These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39096666)

  • 1. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
    Gelissen LMY; Loveless S; Toorop AA; Howlett J; Loeff FC; Rispens T; Killestein J; Tallantyre EC; van Kempen ZLE
    Mult Scler Relat Disord; 2024 Oct; 90():105796. PubMed ID: 39096666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingerprick blood samples to measure serum natalizumab concentrations.
    Toorop AA; Steenhuis M; Loeff FC; Weijers SS; Killestein J; Rispens T; Kempen ZLV
    Mult Scler; 2023 Mar; 29(3):457-460. PubMed ID: 36448735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
    Toorop AA; van Kempen ZLE; Steenhuis M; Nielsen J; Sinnige LGF; van Dijk G; Roosendaal CM; Arnoldus EPJ; Hoitsma E; Lissenberg-Witte BI; de Jong BA; Oosten BWV; Strijbis EMM; Uitdehaag BMJ; Rispens T; Killestein J;
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):482-486. PubMed ID: 36639226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended interval dosing of natalizumab: More evidence in support.
    Toljan K; Conway DS
    Neurotherapeutics; 2024 Apr; 21(3):e00351. PubMed ID: 38531713
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    Toorop AA; Wessels MHJ; Gelissen LMY; Hoitsma E; Zeinstra EMPE; van Rooij LC; van Munster CEP; Vennegoor A; Mostert JP; Wokke BHA; Kalkers NF; Hoogervorst ELJ; van Eijk JJJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige LGF; Kloosterziel ME; Arnoldus EPJ; van Dijk GW; Bouvy WH; Strijbis EMM; van Oosten BW; de Jong BA; Lissenberg-Witte BI; Rispens T; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    J Neurol Sci; 2024 Jul; 462():123102. PubMed ID: 38925067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    van Kempen ZL; Leurs CE; Witte BI; de Vries A; Wattjes MP; Rispens T; Killestein J
    Mult Scler; 2018 May; 24(6):805-810. PubMed ID: 28485678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L; Li X; Goldberg JD; Hoyt T; Christensen A; Metzger RR; Kister I; Foley J
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study.
    Mealli F; Mattei A; Mariottini A; Massacesi L
    Mult Scler; 2024 Jul; 30(8):1077-1080. PubMed ID: 38481074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
    Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L
    Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Toorop AA; Rispens T; Strijbis EM; van Oosten BW; de Jong BA; Uitdehaag BM; Killestein J; van Kempen ZL
    Mult Scler; 2022 Feb; 28(2):323-326. PubMed ID: 34931887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
    Chang I; Muralidharan KK; Campbell N; Ho PR
    J Clin Pharmacol; 2021 Mar; 61(3):339-348. PubMed ID: 32949472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach.
    Borriello G; Ianniello A
    Mult Scler Relat Disord; 2020 Jun; 41():102165. PubMed ID: 32388451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.